Calendar

Berkshire is liquid and no major balance-sheet or governance disqualifier was identified, but its Nov. 2 date and Q3 consensus are supported mainly by third-party estimates, and the checked evidence does not establish positive estimate revisions, business inflection, or required tape signals.

The release supports a modestly positive earnings interpretation, tempered by the Q4 cost and outage outlook. A live quote was $239 at 11:24 UTC on October 22, but no reliable regular-session post-release move was available at this T+1 cutoff. No verified post-print analyst target or estimate revisions were found; zero-valued sentiment fields indicate unavailable measurements, not neutral readings.

Earnings headlines are positive, but the October 21 close was only modestly above the prior close, and available price feeds disagree on the exact closing print; the packet's $694.02 adjusted-close anchor is used for valuation. The quarter beat pre-print consensus, while verified post-print analyst revisions remain unavailable at this T+1 checkpoint. Social, options, short-interest and employee scores are not evidenced in the packet; zero values above denote unavailable inputs, not neutral readings. [Consensus and reaction](https://www.marketbeat.com/earnings/reports/2026-10-21-thermo-fisher-scientific-inc-stock/) [Historical prices](https://stockanalysis.com/stocks/tmo/history/)

Mixed-to-negative immediate reaction: [Investing.com](https://www.investing.com/news/stock-market-news/abbott-laboratories-earnings-analysis-questions-answered-and-next-catalysts-93CH-4963717) reported a 3.42% intraday decline on October 21 and linked weakness to the lower sales-growth outlook; the packet's October 21 adjusted-close anchor is $100.51. Consensus sources disagree by one cent on EPS, and only one specific post-print target cut was verified. Social, options, short-interest and employee measures were unavailable; zero entries above are unavailable-data placeholders, not measured neutral readings.

Earnings news is constructive, but the stock's October 21 close of $166.91 was only about 0.9% above its $165.44 pre-print close, a restrained initial reaction to the beat. That price comparison does not establish why shares moved. Verified post-print analyst revisions are unavailable at this early T+1 checkpoint; social, options, short-interest and employee-sentiment measures were not supplied and the zero fields above denote unavailable data, not measured neutral readings. [historical prices](https://fwnbc.marketminute.com/quote/NQ%3ANTRS/historical)

The October 21 earnings release presents strong balance-sheet growth but an externally reported EPS and revenue miss. The supplied $102.78 anchor and available quote do not establish a post-release regular-session reaction. Verified post-print analyst revisions and target changes are unavailable; their absence is not positive evidence. The stored earnings-document row concerns PNFP, not SSB, and was excluded.

Initial coverage is mixed: reported adjusted EPS was above a pre-release estimate, but year-over-year profit and revenue declined. [Immediate post-release coverage](https://finance.yahoo.com/healthcare/articles/molina-healthcare-nyse-moh-q3-204800968.html) reported an approximately 4.1% after-hours decline; that is not a confirmed full-session reaction. Post-print analyst revisions were unavailable, and the earnings call had not yet been incorporated. Zeroes in unavailable sentiment fields are placeholders, not measured neutral readings.